Antiretroviral pre-exposure prophylaxis implementation in the United States: a work in progress

INTRODUCTION: After the initial approval of the use of tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) by the US Food and Drug Administration in 2012 for anti-HIV pre-exposure prophylaxis (PrEP), uptake was initially limited, but more recent community surveys and expert opinion suggest wider a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayer, Kenneth H, Hosek, Sybil, Cohen, Stephanie, Liu, Albert, Pickett, Jim, Warren, Mitchell, Krakower, Douglas, Grant, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2015
Materias:
PrEP Implementation Science: State-of-the-Art and Research Agenda
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509893/
https://www.ncbi.nlm.nih.gov/pubmed/26198345
http://dx.doi.org/10.7448/IAS.18.4.19980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509893/
https://www.ncbi.nlm.nih.gov/pubmed/26198345
http://dx.doi.org/10.7448/IAS.18.4.19980

Ejemplares similares